8EHQ-0102-14999

DuPont Haskell Laboratory
for Health and Environmental Sciences
Elkton Road, P.O. Box 50
Newark, DE 19714-0050

January 28, 2002

MR 54736

Via Federal Express

Document Processing Center (Mail Code 7407M)
Room 6428
Attention: 8(e) Coordinator
Office of Pollution Prevention and Toxics
U.S. Environmental Protection Agency, ICC Building
1201 Constitution Ave., NW
Washington, D.C. 20460

Dear 8(e) Coordinator:

8EHQ-01-14999

We recently received a copy of a final report describing a 28-day gavage study in rats with the above referenced test material. This letter is to inform you of the results of that study.

The test substance was administered by gavage to groups of 5 male and 5 female Wistar rats at dosages of 0, 45, 135 or 815 mg/kg/day for 28 days. At 815 mg/kg/day, 1 male and 1 female rat died during the last week of dosing. Salivation was noted in most animals from this group, however, the finding was considered to be due to repeated intubation of the irritating test material. Histopathological evidence of minimal to slight forestomach epithelial hyperplasia was seen in most 815 mg/kg/day rats. The study no-observed effect level (NOEL) was 135 mg/kg/day.

Under these experimental conditions, the findings described above appear to be reportable based upon guidance given in the EPA TSCA Section 8(e) Reporting Guide (June 1991).

Sincerely,

A. Michael Kaplan

A. Michael Kaplan, Ph.D.
Director – Regulatory Affairs

Contain NO CBI

AMK/RV:clp
(302) 366-5260

8EHQ-01-14999

RECEIVED
OPPT CBIC
2002 JAN 29 PM 2:54

89020000052